Lidoderm
Publisher: Datamonitor Healthcare
- Description
- Companies
- Contents
- Enquire
Drug Overview
Lidoderm is a medicated plaster containing 5% lidocaine, and was developed by Endo Pharmaceuticals. Lidocaine is an amide-type local anesthetic agent that acts by stabilizing neuronal membranes. It impairs membrane permeability to sodium, which in turn blocks impulse propagation, and thus dampens both peripheral nociceptor sensitization and eventually central nervous system hyperexcitability. It also suppresses neuronal discharge in A delta and C fibers. Lidocaine is also used as an anesthetic agent indicated for production of local or regional anesthesia, and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Lidoderm : Neuropathic pain
LIST OF FIGURES
8 Figure 1: Lidoderm for neuropathic pain – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Lidoderm for neuropathic pain
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Lidoderm for neuropathic pain
12 Figure 4: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Lidoderm drug profile
7 Table 2: Lidoderm Phase III data in neuropathic pain syndromes
13 Table 3: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Mirogabalin 
Sign up to the